CN118922448A - Cd3特异性的去免疫抗体 - Google Patents

Cd3特异性的去免疫抗体 Download PDF

Info

Publication number
CN118922448A
CN118922448A CN202380029580.4A CN202380029580A CN118922448A CN 118922448 A CN118922448 A CN 118922448A CN 202380029580 A CN202380029580 A CN 202380029580A CN 118922448 A CN118922448 A CN 118922448A
Authority
CN
China
Prior art keywords
antibody
seq
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380029580.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·莫斯梅尔
A·布特曼
S·林茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of CN118922448A publication Critical patent/CN118922448A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380029580.4A 2022-03-22 2023-03-21 Cd3特异性的去免疫抗体 Pending CN118922448A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22163663.2 2022-03-22
EP22163663 2022-03-22
PCT/EP2023/057248 WO2023180346A1 (en) 2022-03-22 2023-03-21 Deimmunized antibodies specific for cd3

Publications (1)

Publication Number Publication Date
CN118922448A true CN118922448A (zh) 2024-11-08

Family

ID=80930505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380029580.4A Pending CN118922448A (zh) 2022-03-22 2023-03-21 Cd3特异性的去免疫抗体

Country Status (9)

Country Link
US (1) US20250206819A1 (enExample)
EP (1) EP4496812A1 (enExample)
JP (1) JP2025513714A (enExample)
KR (1) KR20240158351A (enExample)
CN (1) CN118922448A (enExample)
AU (1) AU2023240297A1 (enExample)
CA (1) CA3246381A1 (enExample)
IL (1) IL315591A (enExample)
WO (1) WO2023180346A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025106469A1 (en) * 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
AU2003236728A1 (en) 2002-06-10 2003-12-22 Algonomics N.V. Method for predicting the binding affinity of mhc/peptide complexes
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
ES2742224T3 (es) * 2013-11-07 2020-02-13 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos anti-WT1/HLA
RU2016151235A (ru) * 2014-05-28 2018-06-28 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CA3121699A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules

Also Published As

Publication number Publication date
CA3246381A1 (en) 2023-09-28
US20250206819A1 (en) 2025-06-26
JP2025513714A (ja) 2025-04-30
AU2023240297A1 (en) 2024-10-03
EP4496812A1 (en) 2025-01-29
IL315591A (en) 2024-11-01
WO2023180346A1 (en) 2023-09-28
KR20240158351A (ko) 2024-11-04

Similar Documents

Publication Publication Date Title
US11472880B2 (en) Humanized antibodies for CD3
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
US10815304B2 (en) PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
US20160297881A1 (en) BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2021528973A (ja) 抗ｓｔｅａｐ１抗原結合タンパク質
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
US12428479B2 (en) CLDN18.2-targeting antibody, bispecific antibody and use thereof
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CA3096791A1 (en) Cell engaging binding molecules
US20250206819A1 (en) Deimmunized antibodies specific for cd3
CN120476145A (zh) 靶向cd45的抗体
CN119487070A (zh) 靶向cd117的抗体
KR20250031232A (ko) 인간 인터루킨-4 수용체 알파 항체 글루코코르티코이드 접합체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination